Duration

CDC/ACIP* encourages healthcare professionals to begin vaccinating as soon as vaccine is available and to continue vaccinating throughout the influenza season1


FluMist® helped provide protection for children 24-35 months of age that lasted through the end of the influenza season.2-4
Scroll down to see full Important Safety Information.

Efficacy of FluMist vs Placebo chart
HIDE Footnotes & Study Design

Adapted from Tam JS et al, Pediatr Infect Dis J. 2007;26:619-628.

†A prospective, randomized, double-blind, placebo-controlled trial in vaccine-naïve children 24 to 35 months of age for the 2000-2001 influenza season. Data are representative of the indicated population; full study population is represented in the Prescribing Information.

‡Attack rates for FluMist vs. placebo were 4.1% and 13.3%, respectively.

FluMist® typically ships in time for back-to-school needs

You can give influenza vaccine at regularly scheduled visits, including:

  • Well-child visits
  • Back-to-school checkups
  • Sports physicals

The early ship date will also provide more opportunities for 2-dose adherence in eligible children less than 9 years of age, according to the 2011-2012 CDC/ACIP influenza recommendations. Please see the Prescribing Information

*CDC/ACIP=Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices

Important Safety Information

FluMist® (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of individuals 2-49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children <24 months of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children <5 years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barré syndrome has occurred with prior influenza vaccination, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. Data supporting the safety and effectiveness of FluMist administration in immunocompromised individuals are limited. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring at ≥10% in individuals receiving FluMist and at least 5% greater than in placebo) are runny nose or nasal congestion in recipients of all ages, fever >100°F in children 2-6 years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see accompanying complete Prescribing Information, including Patient Information [PDF PDF].

References
  1. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on lmmunization Practices (ACIP), 2010. MMWR. 2010 Aug 6;59(RR-8):1-62.
  2. FluMist [package insert]. Gaithersburg, MD: Medlmmune, LLC.
  3. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine. 2008;26S:D10-D16.
  4. Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007;26:619-628.